ArticleSarcoma2019

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).

Brigitte C Widemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.